Drug Trial Radar · NCT06570434
Phase 1b/2a in SLE With Budoputug
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2025
Primary completion
Dec 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Tenet MedicinesIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of budoprutug in participants with SLE
Conditions
- Systemic Lupus Erythematosus
- SLE
- B Cells
Interventions
budoprutugDrug
monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: Day 1 through Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.